Key Takeaways
- • The 2020 No Surprises Act, designed to protect patients from out-of-network medical bills, has generated an estimated $5 billion in costs that will likely be passed to patients through higher premiums, undermining the law's original intent.
- • Private equity firms have strategically positioned themselves on both sides of the Independent Dispute Resolution (IDR) process—backing providers who file disputes while simultaneously owning certified IDR entities that arbitrate those same disputes, creating potential conflicts of interest.
- • Private equity-backed providers dominate IDR case filings, overwhelming the dispute resolution system designed to address payment disagreements between providers and health insurers when out-of-network care occurs.
- • At least one private equity firm maintains investments in both a provider using the IDR process and certified IDR entities that adjudicate disputes, raising regulatory and ethical concerns about impartial arbitration.
- • Provider groups, including private equity-backed entities operating as dark money organizations, actively lobbied for the arbitration provision that became embedded in the final version of the No Surprises Act.
Summary
The No Surprises Act, enacted in 2020 as a bipartisan legislative effort, aimed to eliminate surprise medical billing—the practice of charging patients high out-of-network fees for care received at supposedly in-network facilities. While the law has succeeded in reducing surprise bills for patients, research indicates that the legislation has created an estimated $5 billion in costs that will likely be absorbed by patients through increased insurance premiums, effectively transferring the financial burden rather than eliminating it.
The mechanism enabling this outcome centers on the Independent Dispute Resolution (IDR) process, a arbitration venue embedded in the law to resolve payment conflicts between providers and health insurers when they cannot agree on out-of-network payment amounts. Private equity firms have leveraged this process to achieve significant financial gains by strategically positioning themselves on both sides of the arbitration table. Private equity-backed providers consistently rank among the highest filers of IDR disputes, while private equity-owned entities simultaneously function as certified IDR arbitrators responsible for adjudicating these same disputes.
This dual positioning creates structural conflicts of interest. At minimum, one private equity firm maintains concurrent investments in both a provider actively using the IDR process and multiple certified IDR entities that arbitrate disputes. This arrangement enables private equity investors to profit regardless of dispute outcomes—either through favorable arbitration decisions favoring their provider investments or through per-case arbitrator fees ranging from several hundred dollars to nearly $9,000 per dispute.
The arbitration provision itself was not accidental. Provider groups, including private equity-backed organizations operating through dark money structures, actively lobbied for the IDR process during legislative negotiations leading to the No Surprises Act's final version. This advocacy proved strategically valuable, as the resulting system has become overwhelmed by the volume of disputes filed by private equity-backed providers, effectively transforming a patient protection mechanism into a wealth extraction vehicle for alternative investment firms.
The mechanism enabling this outcome centers on the Independent Dispute Resolution (IDR) process, a arbitration venue embedded in the law to resolve payment conflicts between providers and health insurers when they cannot agree on out-of-network payment amounts. Private equity firms have leveraged this process to achieve significant financial gains by strategically positioning themselves on both sides of the arbitration table. Private equity-backed providers consistently rank among the highest filers of IDR disputes, while private equity-owned entities simultaneously function as certified IDR arbitrators responsible for adjudicating these same disputes.
This dual positioning creates structural conflicts of interest. At minimum, one private equity firm maintains concurrent investments in both a provider actively using the IDR process and multiple certified IDR entities that arbitrate disputes. This arrangement enables private equity investors to profit regardless of dispute outcomes—either through favorable arbitration decisions favoring their provider investments or through per-case arbitrator fees ranging from several hundred dollars to nearly $9,000 per dispute.
The arbitration provision itself was not accidental. Provider groups, including private equity-backed organizations operating through dark money structures, actively lobbied for the IDR process during legislative negotiations leading to the No Surprises Act's final version. This advocacy proved strategically valuable, as the resulting system has become overwhelmed by the volume of disputes filed by private equity-backed providers, effectively transforming a patient protection mechanism into a wealth extraction vehicle for alternative investment firms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.